Healthcare & MedTech: CDSCO Registration

Why India's Healthcare and MedTech Sector Demands Attention

India's medical device market is valued at approximately USD 16.97 billion in 2025 and is projected to reach USD 24.85 billion by 2030, growing at a CAGR of 7.93%. For foreign companies evaluating market entry, the combination of 100% FDI under the automatic route, a Production-Linked Incentive (PLI) scheme with an outlay of INR 3,420 crore, and a rapidly expanding domestic demand base creates a compelling investment thesis.

The Union Budget 2025-26 allocated Rs. 99,858 crore (approximately USD 11.48 billion) to healthcare, reinforcing the government's commitment to building India into a global medtech manufacturing hub. Between April 2000 and June 2025, FDI inflow in the medical and surgical appliances sector reached Rs. 27,900 crore (USD 3.96 billion).

However, market entry requires navigating a comprehensive regulatory framework supervised by the Central Drugs Standard Control Organisation (CDSCO). This guide walks foreign companies through every step, from device classification to post-market surveillance.

FDI Policy Framework for Healthcare and MedTech

Sectoral Caps and Route Requirements

India permits 100% FDI under the automatic route for manufacturing medical devices. This means foreign investors do not require prior approval from the government approval route or the Reserve Bank of India before investing. The investment can flow through a wholly owned subsidiary, a joint venture, or an acquisition of an existing Indian entity.

For the broader healthcare sector, the FDI policy allows:

• Medical devices manufacturing: 100% FDI via automatic route
• Hospitals and healthcare infrastructure: 100% FDI via automatic route
• Pharmaceutical manufacturing (greenfield): 100% FDI via automatic route
• Pharmaceutical manufacturing (brownfield): 74% via automatic route; beyond 74% requires government approval

Entity Structure Options

Foreign medtech companies typically enter India through one of three structures:

• Private Limited Company: Most common for manufacturing operations. Requires minimum two directors (one must be a resident director), share capital filing via FC-GPR, and annual compliance under the Companies Act.
• Branch Office: Suitable for import and distribution activities. Requires RBI approval and cannot engage in manufacturing directly.
• Liaison Office: Limited to market research and promotional activities. Cannot generate revenue in India.

For a detailed comparison, see our branch office vs subsidiary comparison.

Understanding CDSCO: India's Medical Device Regulator

The Central Drugs Standard Control Organisation (CDSCO), operating under the Ministry of Health and Family Welfare, is India's national regulatory authority for medical devices. It functions analogously to the US FDA, EU MDR notified bodies, or Japan's PMDA.

CDSCO's mandate covers:

• Pre-market approval and registration of medical devices
• Import licensing for foreign-manufactured devices
• Clinical trial oversight for new devices
• Post-market surveillance through the Materiovigilance Programme of India (MvPI)
• Manufacturing license issuance (in coordination with state drug controllers)

All applications are submitted digitally through the SUGAM portal, CDSCO's online platform for paperless regulatory processing.

Medical Device Classification: Classes A Through D

India follows a risk-based classification system under the Medical Devices Rules, 2017, categorising all devices into four classes:

Classification is determined by the device's intended use, duration of contact with the body, degree of invasiveness, and whether it is active (powered) or passive. Getting the classification right at the outset is critical, as it determines the entire regulatory pathway, documentation requirements, and associated fees.

Step-by-Step CDSCO Registration Process for Foreign Companies

Step 1: Appoint an Authorized Indian Agent (AIA)

Every foreign manufacturer must appoint an Authorized Indian Agent to serve as the local liaison with CDSCO. The AIA handles all submissions, communications, and compliance obligations on behalf of the overseas entity. The AIA must be a legal entity registered in India with a valid drug license or establishment registration.

Step 2: Prepare the Device Master File (DMF) and Plant Master File (PMF)

Documentation requirements include:

• Device Master File (DMF): Design specifications, intended use, materials, biocompatibility data, sterilisation methods, shelf life, labelling
• Plant Master File (PMF): Manufacturing processes, quality control systems, site layout, equipment list, environmental controls
• ISO 13485 certification: Mandatory Quality Management System certification for all device classes
• Clinical evaluation data: Required for Class C and Class D devices. Can be based on clinical investigation in India, clinical data from other jurisdictions, or substantial equivalence to a predicate device

Step 3: Apply Through the SUGAM Portal

Submit Form MD-14 (for import license) through the SUGAM portal. Key documents to upload include:

• Free Sale Certificate from the country of origin
• ISO 13485 certificate
• Device Master File and Plant Master File
• Clinical evaluation report (for Class C/D)
• Labelling and Instructions for Use (IFU)
• Authorization letter appointing the AIA
• Declaration of conformity

Step 4: CDSCO Review and Site Inspection

CDSCO reviews the documentation and may schedule a site inspection of the manufacturing facility. For Class C and D devices, a manufacturing site audit is typical. The inspection verifies compliance with Good Manufacturing Practices (GMP) and ISO 13485 requirements.

Step 5: Obtain Import License (Form MD-15)

Upon successful review, CDSCO issues the import license in Form MD-15. This license authorises the import and distribution of the registered device in India.

Registration Fees and Cost Breakdown

CDSCO fees vary by device classification and activity type:

Beyond CDSCO fees, foreign companies should budget for:

• Authorized Indian Agent fees: INR 3-8 lakh per year depending on scope
• ISO 13485 certification: INR 2-5 lakh (initial audit)
• Clinical evaluation report preparation: INR 5-15 lakh for Class C/D devices
• Regulatory consulting: INR 5-20 lakh depending on complexity

Clinical Trial Waiver Provisions

CDSCO provides a pathway to waive clinical investigation requirements in India if the medical device meets specific criteria:

• The device has been approved by regulatory authorities in the UK, USA, Canada, or Japan
• The device has been marketed in those jurisdictions for at least two years
• Satisfactory safety, performance, and pharmacovigilance data has been submitted to the Central Licensing Authority

This provision significantly reduces time-to-market for devices already approved in GHTF (Global Harmonization Task Force) countries. However, CDSCO retains discretion and may still require Indian clinical data for novel devices or those with insufficient post-market data from reference jurisdictions.

In-Vitro Diagnostic (IVD) Devices: Special Considerations

In-vitro diagnostic medical devices follow the same CDSCO regulatory pathway but have additional requirements that foreign IVD manufacturers must be aware of:

• Classification specifics: IVDs are classified under Classes A through D based on the risk to public health from incorrect results, not from direct patient contact. High-risk IVDs (Class D) include blood grouping reagents, HIV and Hepatitis B/C test kits, and companion diagnostics
• Performance evaluation: IVD devices must demonstrate analytical performance (sensitivity, specificity, accuracy) and clinical performance through evaluation studies. For Class C and D IVDs, CDSCO may require Indian clinical performance data on Indian patient samples
• Reference standards: IVDs must be validated against Indian reference panels where applicable, particularly for infectious disease diagnostics where disease prevalence and strain variations differ from Western populations
• Batch release testing: Certain high-risk IVDs may be subject to batch release testing by CDSCO-designated laboratories before distribution

The IVD market in India is growing rapidly, driven by government programmes like Ayushman Bharat and expanded diagnostic networks in Tier 2 and Tier 3 cities. Foreign IVD companies should consider establishing local production to benefit from the PLI scheme and avoid import dependency.

Regulatory Comparison: CDSCO vs Global Regulators

Foreign manufacturers accustomed to other regulatory regimes should note key differences:

One significant advantage for companies already holding US FDA 510(k)/PMA or EU CE marking is that CDSCO recognises these approvals for clinical trial waiver purposes, provided the two-year marketing history requirement is met.

PLI Scheme and Government Incentives

The Production-Linked Incentive scheme for medical devices offers a 5% incentive on incremental sales of domestically manufactured devices over a five-year performance period (FY 2022-23 to FY 2026-27), with a total government outlay of INR 3,420 crore.

PLI Scheme Performance (as of September 2025)

• 22 greenfield manufacturing projects commissioned
• 50-57 high-end devices covered, including MRI scanners, CT scanners, mammography systems, linear accelerators, heart valves, and stents
• Incremental production and sales exceeding INR 18.70 lakh crore

Medical Device Parks

The Department of Pharmaceuticals is establishing dedicated medical device parks with a total outlay of Rs. 400 crore (maximum Rs. 100 crore per park):

• Tamil Nadu (Oragadam): 350 acres near Chennai, developed by SIPCOT
• Madhya Pradesh (Ujjain): 360 acres in Vikram Udyogpuri, already attracting South Korean investment
• Uttar Pradesh: 350 acres, North India's first dedicated medical device park
• Himachal Pradesh: Financial assistance of Rs. 100 crore approved

These parks offer common infrastructure including testing laboratories, effluent treatment plants, warehousing, and logistics connectivity, reducing setup costs by 25-40% compared to standalone facilities.

Post-Market Surveillance and Ongoing Compliance

After obtaining CDSCO registration, foreign companies must maintain ongoing compliance:

• Materiovigilance Programme of India (MvPI): Mandatory adverse event reporting for all registered devices
• Periodic Safety Update Reports (PSURs): Required for Class C and D devices
• Quality system maintenance: ISO 13485 certification must remain current
• Annual compliance filings: FLA return with RBI, annual returns with ROC, GST compliance, and transfer pricing documentation for related-party transactions

Non-compliance can result in license suspension or cancellation, product recalls, and penalties under the Medical Devices Rules, 2017.

Labelling and Packaging Requirements

Medical devices sold in India must comply with specific labelling requirements under the Medical Devices Rules, 2017. Foreign manufacturers often underestimate these requirements, leading to customs delays and regulatory holds at port.

Mandatory Label Information

• Product name and description: Must match the CDSCO registration exactly
• Name and address of manufacturer: Full legal name and registered address of the foreign manufacturer
• Name and address of Authorized Indian Agent: Must appear on all labels for imported devices
• Batch or lot number: For traceability and recall management
• Date of manufacture and expiry: In DD/MM/YYYY format as per Indian standards
• Storage conditions: Temperature, humidity, and handling instructions
• Unique Device Identification (UDI): India is progressively implementing UDI requirements aligned with global standards
• Import license number: The MD-15 license number must be printed on packaging

Language Requirements

Labels must be in English. If the device is intended for use by patients directly (home-use devices), Hindi labelling may also be recommended. Instructions for Use (IFU) must be comprehensive and in English at minimum.

Import Procedures and Customs Clearance

Once the CDSCO import license is obtained, the actual import process involves several additional steps that foreign companies must plan for:

Customs Documentation

• Import Export Code (IEC): Mandatory for any entity importing goods into India, obtained from the Directorate General of Foreign Trade (DGFT)
• Bill of Entry: Filed electronically through the Indian Customs Electronic Gateway (ICEGATE)
• CDSCO NOC at port: The port officer of CDSCO may inspect consignments and issue a No Objection Certificate before customs clearance
• GST on imports: Integrated GST (IGST) applies at the applicable rate, currently ranging from 5% to 18% depending on the device category

Free Trade Zone and Bonded Warehouse Options

Foreign companies can use Special Economic Zones (SEZs) or bonded warehouses to manage inventory and defer customs duty payments. This is particularly useful for companies distributing devices across multiple Indian states from a central location.

Intellectual Property Protection for MedTech

Foreign medtech companies entering India should proactively protect their intellectual property:

• Patent registration: File with the Indian Patent Office before or concurrently with CDSCO registration. India follows a first-to-file system with a 20-year patent term
• Trademark registration: Protect brand names, logos, and device trade names through the Trademarks Registry
• Design registration: Protect unique device designs and form factors
• Trade secrets: Implement confidentiality agreements with Authorized Indian Agents, distributors, and contract manufacturers

India is a signatory to the Patent Cooperation Treaty (PCT), TRIPS Agreement, and Paris Convention, providing international IP holders with a recognised framework for protection and enforcement.

Tax Structure for Foreign MedTech Companies

Understanding the tax landscape is critical for financial planning:

New manufacturing companies incorporated after October 2019 and commencing production before March 2024 can avail of the concessional corporate tax rate of 15% (effective 17.16% including surcharge and cess), making India one of the most tax-competitive manufacturing destinations globally. Companies should consult with a tax advisory specialist to optimise their structure.

Common Mistakes Foreign MedTech Companies Make

• Misclassifying the device: Classifying a Class C device as Class B to avoid clinical data requirements leads to rejection and delays of 6-12 months
• Inadequate clinical evidence: Submitting literature reviews instead of proper clinical evaluation reports for Class C/D devices
• Ignoring the AIA requirement: Attempting to submit directly without an Authorized Indian Agent results in automatic rejection
• Missing FC-GPR filing deadlines: Foreign investment must be reported to RBI within 30 days of allotment of shares
• Underestimating timelines: Planning for a 3-month registration when Class D devices typically take 9-12 months
• Neglecting state-level manufacturing licenses: Even with CDSCO approval, manufacturing requires separate state-level drug controller permissions
• Not budgeting for the Authorized Indian Agent: The AIA is an ongoing annual cost (INR 3-8 lakh per year), not a one-time expense. Choosing a low-quality AIA to save costs often results in delayed communications with CDSCO and compliance gaps
• Ignoring labelling requirements: Indian labelling standards differ from US and EU requirements. Labels must include the AIA's name and address, import license number, and batch details in the prescribed format. Non-compliant labels cause customs holds and port rejections

Strategic Entry Considerations

Foreign medtech companies should consider several strategic factors when planning their India entry:

Manufacturing vs Import

While importing finished devices is faster to market (6-12 months for registration), establishing local manufacturing unlocks significantly greater benefits: PLI incentives of 5% on incremental sales, access to medical device parks with subsidised infrastructure, the concessional 22% corporate tax rate (effective 25.17%) under Section 115BAA (the 15%/17.16% Section 115BAB rate closed to companies that did not commence manufacturing by 31 March 2024), and stronger positioning for government procurement under the Public Procurement Order that preferences domestically manufactured medical devices.

Distribution and Market Access

India's healthcare market is fragmented across public hospitals (government-run), private hospital chains (Apollo, Fortis, Max, Narayana Health), standalone clinics, and diagnostic centres. Foreign companies should consider appointing multiple regional distributors rather than relying on a single national distributor, as healthcare procurement patterns vary significantly across states and between public and private sectors.

Government Procurement

The Government e-Marketplace (GeM) is the mandatory procurement portal for government hospitals and agencies. Registering on GeM and obtaining the necessary certifications (including Make in India classification where applicable) opens access to the large public healthcare market, which accounts for approximately 30-35% of medical device procurement in India.

Key Takeaways

• India permits 100% FDI under the automatic route for medical device manufacturing, with the market projected to reach USD 24.85 billion by 2030
• CDSCO registration through the SUGAM portal is mandatory for all imported medical devices, with timelines ranging from 30-60 days (Class A/B) to 9-12+ months (Class D)
• The PLI scheme offers a 5% incentive on incremental sales through FY 2026-27, and dedicated medical device parks reduce setup costs by 25-40%
• Clinical trial waivers are available for devices already approved in the US, UK, Canada, or Japan and marketed for at least two years
• Budget INR 10-50 lakh for the complete registration process including consulting, ISO certification, and CDSCO fees, with an additional INR 5-15 lakh annually for compliance